Vergoeding 2019-2023 voor ATC-subgroep L01FX : Overige conjugaten met antilichamen
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021* | 2022* | 2023* | |
|---|---|---|---|---|---|
| L01FX02 Gemtuzumab ozogamicin | 23.632 | 118.996 | 144.157 | 202.844 | 200.087 |
| L01FX04 Ipilimumab | 30.584.675 | 33.913.251 | 32.230.388 | 39.757.181 | 45.779.754 |
| L01FX05 Brentuximab vedotine | 4.345.188 | 5.318.910 | 6.515.310 | 5.172.820 | 5.191.312 |
| L01FX06 Dinutuximab beta | 2.812.200 | 2.343.500 | 3.796.470 | 5.268.188 | 4.152.682 |
| L01FX07 Blinatumomab | 1.551.871 | 2.278.573 | 2.172.871 | 1.791.517 | 3.461.698 |
| L01FX08 Elotuzumab | 622.239 | 1.019.140 | 2.946.149 | 3.645.442 | 2.566.711 |
| L01FX09 Mogamulizumab | . | . | 900.727 | 1.874.218 | 1.766.781 |
| L01FX10 Olaratumab | 955.187 | . | . | . | . |
| L01FX13 Enfortumab vedotine | . | . | . | . | 2.307.642 |
| L01FX14 Polatuzumab vedotine | . | . | 693.845 | 761.138 | 561.047 |
| L01FX18 Amivantamab | . | . | . | . | 194.866 |
| Totaal | 40.894.993 | 44.992.370 | 49.399.916 | 58.473.348 | 66.182.581 |